Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Immunity ; 57(8): 1769-1779.e4, 2024 Aug 13.
Article in English | MEDLINE | ID: mdl-38901428

ABSTRACT

Many infections, including malaria, are associated with an increase in autoantibodies (AAbs). Prior studies have reported an association between genetic markers of susceptibility to autoimmune disease and resistance to malaria, but the underlying mechanisms are unclear. Here, we performed a longitudinal study of children and adults (n = 602) in Mali and found that high levels of plasma AAbs before the malaria season independently predicted a reduced risk of clinical malaria in children during the ensuing malaria season. Baseline AAb seroprevalence increased with age and asymptomatic Plasmodium falciparum infection. We found that AAbs purified from the plasma of protected individuals inhibit the growth of blood-stage parasites and bind P. falciparum proteins that mediate parasite invasion. Protected individuals had higher plasma immunoglobulin G (IgG) reactivity against 33 of the 123 antigens assessed in an autoantigen microarray. This study provides evidence in support of the hypothesis that a propensity toward autoimmunity offers a survival advantage against malaria.


Subject(s)
Autoantibodies , Immunoglobulin G , Malaria, Falciparum , Plasmodium falciparum , Humans , Plasmodium falciparum/immunology , Autoantibodies/immunology , Malaria, Falciparum/immunology , Malaria, Falciparum/parasitology , Child , Child, Preschool , Adult , Immunoglobulin G/immunology , Immunoglobulin G/blood , Female , Mali , Male , Adolescent , Antibodies, Protozoan/immunology , Longitudinal Studies , Infant , Antigens, Protozoan/immunology , Young Adult , Autoantigens/immunology , Seroepidemiologic Studies , Middle Aged
2.
Biomolecules ; 14(1)2024 Jan 12.
Article in English | MEDLINE | ID: mdl-38254700

ABSTRACT

Extensive control efforts have significantly reduced malaria cases and deaths over the past two decades, but in recent years, coupled with the COVID-19 pandemic, success has stalled. The WHO has urged the implementation of a number of interventions, including vaccines. The modestly effective RTS,S/AS01 pre-erythrocytic vaccine has been recommended by the WHO for use in sub-Saharan Africa against Plasmodium falciparum in children residing in moderate to high malaria transmission regions. A second pre-erythrocytic vaccine, R21/Matrix-M, was also recommended by the WHO on 3 October 2023. However, the paucity and limitations of pre-erythrocytic vaccines highlight the need for asexual blood-stage malaria vaccines that prevent disease caused by blood-stage parasites. Few asexual blood-stage vaccine candidates have reached phase 2 clinical development, and the challenges in terms of their efficacy include antigen polymorphisms and low immunogenicity in humans. This review summarizes the history and progress of asexual blood-stage malaria vaccine development, highlighting the need for novel candidate vaccine antigens/molecules.


Subject(s)
Malaria Vaccines , Malaria , Child , Humans , Plasmodium falciparum , Pandemics , Erythrocytes
SELECTION OF CITATIONS
SEARCH DETAIL